HUP0300032A2 - Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition - Google Patents
Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical compositionInfo
- Publication number
- HUP0300032A2 HUP0300032A2 HU0300032A HUP0300032A HUP0300032A2 HU P0300032 A2 HUP0300032 A2 HU P0300032A2 HU 0300032 A HU0300032 A HU 0300032A HU P0300032 A HUP0300032 A HU P0300032A HU P0300032 A2 HUP0300032 A2 HU P0300032A2
- Authority
- HU
- Hungary
- Prior art keywords
- alpha
- prevention
- treatment
- adrenoreceptor
- preparation
- Prior art date
Links
- 102100036666 Alpha-2B adrenergic receptor Human genes 0.000 title abstract 3
- 101710175728 Alpha-2B adrenergic receptor Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229940082496 Adrenoreceptor antagonist Drugs 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
A találmány az (A), (B), (C), (D) vagy (E) képletű vegyületekre ésezek gyógyászatilag elfogadható sóira vonatkozik, amelyekgyógyszerként alkalmazhatók. A találmány kiterjed az alfa-2B-adrenoreceptor antagonisták alkalmazására emlősöknél alfa-2B-adrenoreceptor által közvetített betegségek kezelésére vagymegelőzésére alkalmas gyógyszerkészítmény előállítására. ÓThe invention relates to compounds of formula (A), (B), (C), (D) or (E) and their pharmaceutically acceptable salts, which can be used as medicine. The invention covers the use of alpha-2B-adrenoreceptor antagonists for the production of pharmaceutical preparations suitable for the treatment or prevention of diseases mediated by alpha-2B-adrenoreceptors in mammals. HE
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18202100P | 2000-02-11 | 2000-02-11 | |
FI20000303A FI20000303A0 (en) | 2000-02-14 | 2000-02-14 | Compounds Useful for the Treatment or Prevention of Alpha-2B Adrenoceptor Mediated Disease |
PCT/FI2001/000105 WO2001058454A1 (en) | 2000-02-11 | 2001-02-07 | Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0300032A2 true HUP0300032A2 (en) | 2003-05-28 |
HUP0300032A3 HUP0300032A3 (en) | 2006-01-30 |
Family
ID=26160944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300032A HUP0300032A3 (en) | 2000-02-11 | 2001-02-07 | Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1253926A1 (en) |
JP (1) | JP2003522148A (en) |
KR (1) | KR20020080413A (en) |
AU (1) | AU780802B2 (en) |
BR (1) | BR0108221A (en) |
CA (1) | CA2399421A1 (en) |
CZ (1) | CZ20022884A3 (en) |
EA (1) | EA200200846A1 (en) |
EE (1) | EE200200435A (en) |
GE (1) | GEP20043356B (en) |
HR (1) | HRP20020746A2 (en) |
HU (1) | HUP0300032A3 (en) |
IL (1) | IL151017A0 (en) |
IS (1) | IS6476A (en) |
MX (1) | MXPA02007454A (en) |
MY (1) | MY133957A (en) |
NO (1) | NO20023773D0 (en) |
NZ (1) | NZ520500A (en) |
PL (1) | PL357872A1 (en) |
SK (1) | SK11472002A3 (en) |
WO (1) | WO2001058454A1 (en) |
YU (1) | YU59102A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI116940B (en) | 2001-07-20 | 2006-04-13 | Juvantia Pharma Ltd Oy | New N-pyrimidinyl para-aminobenzenesulfonamide derivatives as Alpha-2B adrenoceptor antagonists, useful for treating e.g. coronary heart disease, myocardial infarction, angina, restenosis and hypertension |
RU2004105035A (en) * | 2001-07-20 | 2005-06-27 | Ой Ювантиа Фарма Лтд (Fi) | COMPOUNDS USEFUL FOR TREATING OR PREVENTING A DISEASE MEDIATED BY ALPHA-2B-ADRENOCEPTOR |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8416432D0 (en) * | 1984-06-28 | 1984-08-01 | Wyeth John & Brother Ltd | Benzoquinolizines |
RU2086544C1 (en) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity |
US6150389A (en) * | 1994-07-11 | 2000-11-21 | Allergan Sales, Inc. | Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents |
-
2001
- 2001-02-07 PL PL01357872A patent/PL357872A1/en not_active Application Discontinuation
- 2001-02-07 CA CA002399421A patent/CA2399421A1/en not_active Abandoned
- 2001-02-07 NZ NZ520500A patent/NZ520500A/en unknown
- 2001-02-07 EA EA200200846A patent/EA200200846A1/en unknown
- 2001-02-07 JP JP2001557564A patent/JP2003522148A/en active Pending
- 2001-02-07 KR KR1020027010329A patent/KR20020080413A/en not_active Application Discontinuation
- 2001-02-07 EE EEP200200435A patent/EE200200435A/en unknown
- 2001-02-07 MX MXPA02007454A patent/MXPA02007454A/en unknown
- 2001-02-07 BR BR0108221-3A patent/BR0108221A/en not_active IP Right Cessation
- 2001-02-07 YU YU59102A patent/YU59102A/en unknown
- 2001-02-07 EP EP01907585A patent/EP1253926A1/en not_active Withdrawn
- 2001-02-07 HU HU0300032A patent/HUP0300032A3/en unknown
- 2001-02-07 AU AU35510/01A patent/AU780802B2/en not_active Ceased
- 2001-02-07 IL IL15101701A patent/IL151017A0/en unknown
- 2001-02-07 SK SK1147-2002A patent/SK11472002A3/en unknown
- 2001-02-07 GE GE4893A patent/GEP20043356B/en unknown
- 2001-02-07 WO PCT/FI2001/000105 patent/WO2001058454A1/en not_active Application Discontinuation
- 2001-02-07 CZ CZ20022884A patent/CZ20022884A3/en unknown
- 2001-02-09 MY MYPI20010579A patent/MY133957A/en unknown
-
2002
- 2002-07-19 IS IS6476A patent/IS6476A/en unknown
- 2002-08-09 NO NO20023773A patent/NO20023773D0/en not_active Application Discontinuation
- 2002-09-11 HR HRP20020746 patent/HRP20020746A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ520500A (en) | 2005-01-28 |
HUP0300032A3 (en) | 2006-01-30 |
EE200200435A (en) | 2003-12-15 |
BR0108221A (en) | 2003-03-05 |
JP2003522148A (en) | 2003-07-22 |
MXPA02007454A (en) | 2004-08-23 |
IL151017A0 (en) | 2003-02-12 |
KR20020080413A (en) | 2002-10-23 |
CZ20022884A3 (en) | 2003-02-12 |
EA200200846A1 (en) | 2002-12-26 |
NO20023773L (en) | 2002-08-09 |
YU59102A (en) | 2005-11-28 |
MY133957A (en) | 2007-11-30 |
IS6476A (en) | 2002-07-19 |
WO2001058454A1 (en) | 2001-08-16 |
AU780802B2 (en) | 2005-04-21 |
AU3551001A (en) | 2001-08-20 |
CA2399421A1 (en) | 2001-08-16 |
GEP20043356B (en) | 2004-04-13 |
EP1253926A1 (en) | 2002-11-06 |
PL357872A1 (en) | 2004-07-26 |
HRP20020746A2 (en) | 2004-12-31 |
SK11472002A3 (en) | 2003-02-04 |
NO20023773D0 (en) | 2002-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115484T1 (en) | UNIONS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND CONCLUSIONS, AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES AND DISEASE | |
MXPA03005464A (en) | Antiviral agents. | |
UA92181C2 (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimers disease | |
NO20052739L (en) | CCR5 antagonists as drugs | |
EE200300033A (en) | Cyclopentanoindoles, their use in the preparation of a medicament, and the pharmaceutical composition containing them | |
UA90858C2 (en) | Controlled-release formulations containing vardenafil | |
ATE404552T1 (en) | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE | |
UA86614C2 (en) | Compound having kinase ingibitor activity, pharmaceutical composition containing thereof and use thereof for the preparation of medicine | |
CA2534570A1 (en) | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | |
MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
NO20093464L (en) | New drug mixtures based on anti-cholinergically effective compounds and beta-mimetics | |
ATE361287T1 (en) | NEW INDOL-2-ON DERIVATIVES | |
SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
ATE402176T1 (en) | PYRROLIDINE AND AZETIDINE COMPOUNDS ALSCCR5 ANTAGONISTS | |
TW200606164A (en) | New compounds | |
WO2002088100A3 (en) | Deuterated 3-piperidinopropiophenone and medicaments containing said compounds | |
BRPI0411673A (en) | compound, pharmaceutically acceptable salt, pharmaceutical composition, and use of a compound | |
SE0104331D0 (en) | Novel compounds | |
TW200800984A (en) | New compounds | |
HUP0400553A2 (en) | Pharmaceutical compositions | |
SE0102440D0 (en) | New compound | |
CY1110401T1 (en) | PRODUCTION OF 1-PHENYLCOCARCAROXYLIC ACIDS FOR TREATMENT OF NEUROCOLOGICAL DISEASES | |
ATE400563T1 (en) | NEW NEUROKININ ANTAGONISTS FOR USE AS MEDICINAL PRODUCTS | |
WO2005082884A3 (en) | 2-pyridin-2yl-pyrimidine derivatives useful in the treatment of gastro-esophagea l reflux disease |